BIOKAD, AO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN

Phase 3

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions: Biological: eculizumab

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-29

Lead Sponsor: Biocad

Target Recruit Count: 24

Registration Number: NCT06987864

Locations: 🇷🇺
Territorial State Budgetary Healthcare Institution "Territorial Clinical Hospital", Barnaul, Russian Federation
🇷🇺
State Autonomous Healthcare Institution "S.V. Belyaev Kuzbass Regional Clinical Hospital", Kemerovo, Russian Federation
🇷🇺
Federal State Budgetary Institution of Science "Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency", Kirov, Russian Federation

and more 8 locations

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Biological: Divozilimab

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Biocad

Target Recruit Count: 44

Registration Number: NCT06987851

Locations: 🇷🇺
Vyacheslav Andreyevich Dudin, Kirov, Russian Federation
🇷🇺
Dmitry Vladimirovich Pokhabov, Krasnoyarsk, Russian Federation
🇷🇺
Ivan Aleksandrovich Shchukin, Moscow, Russian Federation

and more 12 locations

Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: BCD-261, pre-specified therapeautic dose X
Drug: BCD-261, dose 1
Drug: BCD-261, dose 2
Drug: BCD-261, dose 3
Drug: BCD-261, dose 4
Drug: BCD-261, dose 5
Drug: BCD-261, dose 6
Drug: BCD-261, pre-specified therapeautic dose Y

First Posted Date: 2024-12-04

Last Posted Date: 2024-12-16

Lead Sponsor: Biocad

Target Recruit Count: 48

Registration Number: NCT06715540

Locations: 🇷🇺
"Meditsinskiy teсhnologiy Maly", St. Petersburg, Russian Federation

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Phase 3

Recruiting

Conditions: Hemophilia B

First Posted Date: 2024-11-21

Last Posted Date: 2025-06-13

Lead Sponsor: Biocad

Target Recruit Count: 24

Registration Number: NCT06700096

Locations: 🇷🇺
Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation
🇷🇺
Federal State Budgetary Organization of Science "Kirov Research Institute of Hematology and Blood Transfusions of Federal Medical Biological agency", Kirov, Russian Federation
🇷🇺
Federal State Budgetary Institution "National Medical Research Centre for Hematology" of the Ministry of Health of Russian Federation (Department of Clinical Diagnostics for Hematology and Hemostasis Disorders), Moscow, Russian Federation

and more 8 locations

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma

Phase 2

Recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: BCD-248

First Posted Date: 2024-10-31

Last Posted Date: 2025-02-04

Lead Sponsor: Biocad

Target Recruit Count: 100

Registration Number: NCT06668792

Locations: 🇷🇺
State budgetary healthcare institution of the Sverdlovsk region "Sverdlovsk regional clinical hospital №1", Ekaterinburg, Russian Federation
🇷🇺
SBHI of the Kaliningrad region "Central City Clinical Hospital", Kaliningrad, Russian Federation
🇷🇺
SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigala", Kazan, Russian Federation

and more 17 locations

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Phase 3

Active, not recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Adalimumab
Drug: Netakimab
Drug: Placebo

First Posted Date: 2024-10-15

Last Posted Date: 2025-06-24

Lead Sponsor: Biocad

Target Recruit Count: 140

Registration Number: NCT06640517

Locations: 🇷🇺
Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation, Barnaul, Russian Federation
🇷🇺
State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary", Chelyabinsk, Russian Federation
🇷🇺
State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology", Ekaterinburg, Russian Federation

and more 11 locations

Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Phase 3

Recruiting

Conditions: Advanced Melanoma
Melanoma (Skin)

Interventions: Drug: Opdivo
Drug: BCD-263

First Posted Date: 2024-10-14

Last Posted Date: 2024-10-14

Lead Sponsor: Biocad

Target Recruit Count: 392

Registration Number: NCT06640530

Locations: 🇧🇾
Healthcare Institution "Brest Regional Oncological Dispensary", Brest, Belarus
🇧🇾
Health Institution "Gomel Regional Clinical Oncology Center", Gomel, Belarus
🇧🇾
Healthcare Institution "Minsk City Clinical Cancer Center", Minsk, Belarus

and more 41 locations

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

Phase 3

Active, not recruiting

Conditions: Axial Spondyloarthritis

Interventions: Biological: anti-TRBV9 monoclonal antibody infusions
Other: Placebo infusions
Drug: Adalimumab subcutaneous injection
Other: Placebo subcutaneous injection

First Posted Date: 2024-03-27

Last Posted Date: 2024-06-03

Lead Sponsor: Biocad

Target Recruit Count: 421

Registration Number: NCT06333210

Locations: 🇧🇾
1St City Clinical Hospital, Minsk, Minsk, Belarus
🇧🇾
State Institution "Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology", Minsk, Belarus
🇷🇺
KGBU "City Hospital No. 4 named after N.P. Gull, Barnaul", Barnaul, Russian Federation

and more 29 locations

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Darzalex
Drug: BCD-264

First Posted Date: 2024-03-06

Last Posted Date: 2024-03-06

Lead Sponsor: Biocad

Target Recruit Count: 252

Registration Number: NCT06296121

Locations: 🇷🇺
Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation
🇷🇺
Sverdlovsk Regional Clinical Hospital No. 1, Ekaterinburg, Russian Federation
🇷🇺
Kuzbass Regional Clinical Hospital named after S.V. Belyaev, Kemerovo, Russian Federation

and more 11 locations

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

Phase 1

Active, not recruiting

Conditions: Hemophilia A

Interventions: Genetic: ANB-010, dose 1
Genetic: ANB-010, dose 3
Genetic: ANB-010, dose 2

First Posted Date: 2023-12-29

Last Posted Date: 2025-04-24

Lead Sponsor: Biocad

Target Recruit Count: 50

Registration Number: NCT06185335

Locations: 🇷🇺
State Autonomous Institution for Healthcare "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Russian Federation
🇷🇺
State Autonomous Institution for Healthcare of Sverdlovsk region "Sverdlovsk Regional Clinical Hospital №1", Ekaterinburg, Russian Federation
🇷🇺
State budgetary healthcare institution Leningrad Regional Clinical Hospital, Gatchina, Russian Federation

and more 14 locations

AI-Powered Research

Premium Access

BIOKAD, AO

An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A